As the 2020 flu season approaches, the nasal-sprayed flu vaccine Flumist may play a major role.

Influenza virus is a human and animal influenza RNA virus, in the classification, influenza virus belongs to the positive mucus virus, it will cause acute upper respiratory tract infections, and through the rapid spread of air, there are often periodic pandemics around the world.
influenza virus can cause more serious symptoms, such as pneumonia or heart and lung failure, in older people or children with weak immunity and in some patients with immune disorders.
, seasonal influenza vaccines have historically contained three strains of influenza A: influenza A virus (H1N1), influenza A strain (H3N2), and influenza B strain.
FluMist is a nasal spray-type influenza vaccine that is given through the nasal cavity and is the first nasal-sprayed four-price influenza vaccine available for people ages 2 to 49.
FluMist vaccine can prevent influenza A(HINI, H3N2 strains, 1 or 2 influenza B) viruses.
astraZenepin announced today that it will send its first Flumist four-price vaccine to the United States during the upcoming flu season.
the U.S. Centers for Disease Control and Prevention (CDC) recently stressed the importance of flu vaccination rates in the 2020 flu season to ease pressure on the health care system.
if COVID-19 continues to be endemic during this period, vaccination against influenza can ease the burden on the health care system.
astraZeneil also increased fluminist production by more than 25 per cent over previous plans.
Makar, senior vice president of breathing and immunology at AstraZeneca USA, said: "AstraZeneca has a long history of protecting public health and this year is critical given the COVID-19 pandemic.
, AstraZenezen has increased production capacity and accelerated vaccine development."
.